Valuation
- Market cap
- 2,762,881,000
- Revenue TTM
- $190,410,000
- Net income TTM
- $20,890,000
- PE ratio
- 29.94
- Forward PE
- 14.46
- Profit margin
- 10.97%
- Debt to equity
- 0.10
Trading
- Volume
- 4,968,800
- Avg volume
- 3,907,030
- Day's range
- $52.98 – $53.01
- Shares out
- 52,120,000
- Stochastic %K
- 100%
- Beta
- -2.22
- Analysts
- Hold
- Price target
- $53.00
Company profile
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorpo...
Show more
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 213 8444
- Website
- https://soleno.life
- Address
- 100 Marine Parkway, Suite 400, Redwood City, United States
Latest news
No headlines yet.
